Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7898068 | 0.90 | HTR2C (0.60) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL23326197 | 0.89 | HTR2C (0.58) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL29775341 | 0.89 | HTR2C (0.58) | HTR2CHTR2AHTR2B | |
| SCHEMBL2707057 | 0.87 | HTR2C (0.63) | HTR2CSLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL1266168 | 0.83 | HTR2C (0.63) | HTR2CSLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL5020026 | 0.82 | HTR2C (0.66) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL1093945 | 0.82 | HTR2C (0.61) | HTR2CSLC6A2SLC6A4SLC6A3PTGDR2 | |
| SCHEMBL12491641 | 0.82 | HTR2C (0.54) | HTR2CSLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL6815422 | 0.82 | HTR2C (0.61) | HTR2CSLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL29775383 | 0.81 | HTR2A (0.63) | HTR2CHTR2AHTR6HTR1AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0630887-B1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LTD (GB) | 1999-07-28 | — | — | EP | claimed |
| US-5654299-A | TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | claimed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | claimed |
| EP-3468961-B1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-06-10 | — | — | EP | disclosed |
| EP-3468961-B1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-06-10 | — | — | EP | disclosed |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | GALAPAGOS NV (BE) | 2020-02-04 | — | — | US | disclosed |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | GALAPAGOS NV (BE) | 2020-02-04 | — | — | US | disclosed |
| US-20190300503-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-03 | — | — | US | disclosed |
| US-20190300503-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-03 | — | — | US | disclosed |
| WO-2017211667-A1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2017-12-14 | — | — | WO | disclosed |
| US-20040106623-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-6706716-B2 | NERVOUS SYSTEM DISORDERS; HYPOTENSIVE AGENTS; INCONTINENCE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-03-16 | — | — | US | disclosed |
| US-20020028760-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | H. LUNDBECK A/S (DK) | 2002-03-07 | — | — | US | disclosed |
| EP-1100794-A1 | COMPOUNDS SPECIFIC FOR THE HUMAN $g(a) 1d? ADRENERGIC RECEPTOR AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000004012-A9 | COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000004012-A1 | COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-01-27 | — | — | WO | disclosed |
| EP-0630887-B1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LTD (GB) | 1999-07-28 | — | — | EP | disclosed |
| US-5654299-A | TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | disclosed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106623-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | ADRA1D, ADRA1A, ADRB1 | HTR2C 143/4885SLC6A2 113/4885SLC6A4 502/4885 |
| US-20020028760-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | ADRA1D, ADRA1A, ADRB1 | HTR2C 314/4885SLC6A2 109/4885SLC6A4 522/4885 |
| US-20190300503-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | ADAMTS5, ADAMTS4, ADAMTS1 | HTR2C 1172/4885SLC6A2 4484/4885SLC6A4 1647/4885 |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | ADAMTS5, ADAMTS4, ADAMTS1 | HTR2C 1171/4885SLC6A2 4596/4885SLC6A4 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.